NEJM Evidence Publication in Heart Failure by Nordic Bioscience and Collaborators

Research published in NEJM Evidence positions Nordic Bioscience’s PRO-C6 as next-generation biomarker assay for trial enrichment in HFpEF.
We are extremely proud to be able to announce such a publication.
This was made possible with the help of an unrelenting scientific team. It took several years of dedication and collaboration together with Bristol Myers Squibb and the University of Pennsylvania to achieve this level of scientific excellence.
Morten Karsdal, CEO of Nordic Bioscience reflects on this historic landmark.
Read the press release here: www.nordicbioscience.com/abou...